Cordotomy in Reducing Pain in Patients With Advanced Cancer

Status Recruiting

Clinical Trial Summary

This trial studies how well cordotomy works in reducing pain in patients with cancer that has spread to other places in the body (advanced). Cordotomy is performed on the spinal cord with a needle and guided by computed tomography scans and is designed to help reduce pain. This study is being done to learn if a cordotomy reduces pain in patients with unmanageable cancer pain.

Clinical Trial Description

PRIMARY OBJECTIVES: I. Assess the efficacy of cordotomy for patients with unilateral advanced cancer pain. SECONDARY OBJECTIVES: I. Define the patient experience of cordotomy for cancer pain refractory to palliative care. II. Determine whether magnetic resonance imaging (MRI) can be used as a noninvasive biomarker for a successful cordotomy. OUTLINE: Patients are randomized to 1 of 2 groups. GROUP I: Patients undergo a cordotomy over 1-2 hours. GROUP II: Patients receive morphine via injection into the spine and undergo a fake cordotomy over 1-2 hours. After completion of study, patients are followed up at 2 weeks and once every month for up to 6 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04119037
Study type	Interventional
Source	M.D. Anderson Cancer Center
Contact	Eduardo Bruera
Phone	713-792-6084
Email	ebruera@mdanderson.org
Status	Recruiting
Phase	N/A
Start date	September 16, 2019
Completion date	December 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03671226` - Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center	N/A
Recruiting	`NCT05048160` - A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm	Phase 1/Phase 2
Active, not recruiting	`NCT03287492` - RCT of QPS vs General Information Sheet	N/A
Recruiting	`NCT01549067` - The Real Clinical Background of Advanced Colorectal Cancer Treatment Situation Survey	N/A
Recruiting	`NCT04067336` - First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia	Phase 1/Phase 2
Recruiting	`NCT04585750` - The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)	Phase 1/Phase 2
Completed	`NCT02823652` - Pre-Test Genetic Education and Remote Genetic Counseling in Communicating Tumor Profiling Results to Patients With Advanced Cancer	N/A
Completed	`NCT00244972` - Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer	Phase 1
Recruiting	`NCT06297642` - TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.	Phase 1
Active, not recruiting	`NCT01582191` - Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer	Phase 1
Active, not recruiting	`NCT03856060` - Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits	N/A
Completed	`NCT04186884` - Caregiver Burden, Quality of Life, and Symptom Distress at Different Palliative Cancer Care Settings
Completed	`NCT02583269` - Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery	Phase 1
Withdrawn	`NCT03868423` - Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers	Phase 2
Terminated	`NCT02940223` - Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer	Phase 2
Active, not recruiting	`NCT01552434` - Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease	Phase 1
Active, not recruiting	`NCT03021486` - Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer	Phase 2/Phase 3
Recruiting	`NCT03203525` - Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer	Phase 1
Completed	`NCT01624766` - Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers	Phase 1
Not yet recruiting	`NCT06394713` - A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors	Phase 1/Phase 2